[ad_1]
Aurora Cannabis Inc (NYSE: ACB) announced Thursday that the Luxembourg Ministry of Health has named its European subsidiary, Aurora Deutschland, the exclusive supplier of a second national delivery of medical cannabis.
Aurora has won the rights by offer of sale to the Division of Pharmacy and Medicines of Luxembourg.
This order is the second Aurora of the Luxembourg government. Although its quantity is small, the management considers that it is a validation.
Why is it important
"In addition to the many achievements of our European team, which also includes our recent selection as one of the three companies to establish a domestic production in Germany, our expanded supply agreement with Luxembourg strengthens the capacity of the company." Aurora to act as a trusted partner Neil Belot, Director of Global Development for Aurora, said in a press release that the needs were complex.
The agreement also strengthens Aurora's global dynasty.
"As an established European market leader, Aurora is uniquely positioned to capitalize on the significant advantage we have as a novice in adapting to the growth of new markets for medical cannabis as opportunities arise, "said Maximilian Weinberg, associate director of Aurora's business development for the EU, said.
Shares of Aurora closed Wednesday at $ 8.59 per share and traded slightly higher Thursday on news.
Related links:
Options negotiator earns $ 239K on Aurora cannabis before winning
Signs: Aurora cannabis-related technical escape may be imminent
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source link